Asthma drug enerzair under Real-World watch

NCT ID NCT05274425

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tracks 600 adults with asthma who are already prescribed Enerzair inhaler. Over 24 weeks, researchers will monitor side effects and how well the drug controls asthma in everyday life. No new treatment is given; it simply observes routine care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Enerzair (indacaterol/glycopyrronium/mometasone) inhaler
What this could lead to: If successful, this study could confirm that Enerzair works well and is safe for everyday asthma control in a broad range of patients.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It only follows patients for 24 weeks, so long-term effects are not assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Novartis Investigative Site

Daegu, Dalseo gu, 42602, South Korea
Novartis Investigative Site

Wŏnju, Gangwon-do, 26426, South Korea
Novartis Investigative Site

Bucheon-si, Gyeonggi-do, 14584, South Korea
Novartis Investigative Site

Bundang Gu, Gyeonggi-do, 13620, South Korea
Novartis Investigative Site

Goyang-si, Gyeonggi-do, 10475, South Korea
Novartis Investigative Site

Yangsan, Gyeongsangnam-do, 50612, South Korea
Novartis Investigative Site

Jeonju, Jeollabuk-do, 54907, South Korea
Novartis Investigative Site

Suncheon, Jeollanam-do, 540-719, South Korea
Novartis Investigative Site

Cheongju-si, North Chungcheong, 28644, South Korea
Novartis Investigative Site

Seoul, Seoul, 06351, South Korea
Novartis Investigative Site

Busan, 49201, South Korea
Novartis Investigative Site

Daegu, 705703, South Korea
Novartis Investigative Site

Gwangju, 501171, South Korea
Novartis Investigative Site

Gyeonggi-do, 14353, South Korea
Novartis Investigative Site

Gyeongsangnam Do, 630-522, South Korea
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Seoul, 04763, South Korea
Novartis Investigative Site

Seoul, 05505, South Korea
Novartis Investigative Site

Seoul, 06273, South Korea
Novartis Investigative Site

Seoul, 134 727, South Korea
Novartis Investigative Site

Seoul, 2447, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.